Mission and leadership
Our mission in the UK
Akcea Therapeutics UK is a biotechnology company focused on helping patients living with serious and rare diseases.
Our priority is to bring transformative medicines to patients by understanding patient and healthcare professional needs. We are working with the National Health Service (NHS) to ensure access is available to patients who need these treatments.
About Akcea Therapeutics UK
Akcea Therapeutics, a wholly-owned subsidiary of Ionis Pharmaceuticals, was established in early 2015 and is headquartered in Boston, Massachusetts. Akcea Therapeutics developed an initial presence in the UK in October 2016 and a UK and European head office in Surrey in 2018. It is now on its way to becoming a truly global company with other offices across Europe and the World.
We have a robust portfolio of licensed and developmental stage drugs covering multiple targets and diseases, using advanced RNA-targeted antisense oligonucleotides (ASO).
Our immediate focus is to make our approved products for hereditary transthyretin amyloidosis (hATTR) and familial chylomicronaemia syndrome (FCS) available to patients throughout the UK.
Our core team in the UK
The team at Akcea Therapeutics UK brings together a range of collective experience. We cultivate strong partnerships with patient organisations, healthcare professionals, and governing bodies to advance critically needed therapies for the benefit of patients living with these serious rare diseases.